What do, can and should we learn from models to evaluate potential anticancer agents?

  • Burchill S
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Transfer of new anticancer agents from bench to clinical trial takes in excess of 10 years and costs up to US $500 million. Despite this massive commitment, many more new agents fail in the clinical trials than are successful. The poor performance of many investigational anticancer agents in the clinic implies that the preclinical models used to evaluate them are flawed, inappropriately used or the information they generate is misinterpreted. This article reviews current practice and the range of preclinical models available. The author provides a personal perspective on what information is needed and how in the future this might best be obtained from preclinical models to more effectively inform the transfer of novel, active agents into clinical practice. © 2006 Future Medicine Ltd.

Author-supplied keywords

  • LC50
  • RNA interference
  • accuracy
  • adolescent disease
  • antiangiogenic activity
  • antineoplastic activity
  • antineoplastic agent
  • automated pattern recognition
  • breast cancer
  • cancer model
  • cancer research
  • cancer resistance
  • cell interaction
  • childhood cancer
  • clinical practice
  • clinical trial
  • clonogenic assay
  • colon polyposis
  • correlation function
  • cost effectiveness analysis
  • culture medium
  • drug efficacy
  • drug screening
  • drug sensitivity
  • drug specificity
  • drug targeting
  • erlotinib
  • familial cancer
  • gefitinib
  • gene expression regulation
  • genetic engineering
  • gleevec
  • green fluorescent protein
  • growth inhibition
  • health care availability
  • high risk patient
  • high throughput screening
  • hollow fiber
  • human
  • imatinib
  • in vitro study
  • in vivo study
  • iressa
  • malignant transformation
  • mathematical model
  • maximum tolerated dose
  • metastasis
  • nephroblastoma
  • nonhuman
  • oncogene
  • ovary cancer
  • pathophysiology
  • polyvinylidene fluoride
  • prediction
  • priority journal
  • prodrug
  • retinoblastoma
  • review
  • signal transduction
  • sulforhodamine B
  • tarceva
  • treatment failure
  • tumor growth
  • tumor spheroid
  • tumor suppressor gene
  • tumor xenograft
  • xenotransplantation

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • S A Burchill

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free